Cytokine Expression in Psoriasis Patients with and Without Joint Involvement

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-08-17

Study Completion Date

2026-08-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the resarch is to study the cytokine profile of patients with psoriatic arthritis and psoriasis in order to better understand the pathophysiology of the disease and the contribution of cytokines to the presence or absence of joint involvement. This research will compare cytokines levels in sera, in PBMC culture after LPS or CD3/CD28 agonist antibodies, and in skin biopsy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

IL-17 Role in Variants of Psoriasis

NCT02078297

Scalp Psoriasis Pustular Palmo-plantar Psoriasis Non-pustular Palmo-plantar Psoriasis +2 more

COMPLETED

Interleukin 38 as a Biomarker for Metabolic Syndrome in Psoriatic Patients

NCT05076812

Psoriasis

UNKNOWN

Exploration of the Cellular and Molecular Mechanisms in Patients Receiving Biotherapies Targeting the IL-23/IL-17 Axis in Cutaneous Psoriasis

NCT05111210

Psoriasis

RECRUITING

Association Between the Occurrence of a Clinical RElapse and Gut MIcrobiota Modifications: a Cohort Study of Patients With pSOriasis

NCT06055699

Psoriasis Microbial Colonization

NOT_YET_RECRUITING

Study of Psoriatic Arthritis

NCT00001420

Psoriasis Psoriatic Arthritis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Psoriatic arthritis and Cutaneous Psoriasis are polygenic inflammatory disorders with high burden on the quality of life of patients. Pathophysiology of those disease remain incompletely understood. Recent publications seem to demonstrate an implication of IL-1 family cytokines in the pathogenesis of both diseases. In the literature, results are discordant and focus mainly on cytokines levels in serum of patients. Moreover, few studies compare psoriatic arthritis patients with cutaneous psoriasis patients. We propose here to study cytokines profiles of patients with those conditions in sera, after ex-vivo stimulation of peripheral blood mononuclear cells, and in skin biopsies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psoriasis Psoriatic Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Psoriasis

Group Type EXPERIMENTAL

Blood sample collection

Intervention Type OTHER

Blood sample collection

Skin sample collection

Intervention Type OTHER

Skin sample collection

Psoriatic arthritis

Group Type EXPERIMENTAL

Blood sample collection

Intervention Type OTHER

Blood sample collection

Skin sample collection

Intervention Type OTHER

Skin sample collection

Controls

Group Type ACTIVE_COMPARATOR

Blood sample collection

Intervention Type OTHER

Blood sample collection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood sample collection

Intervention Type OTHER

Skin sample collection

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* For psoriasis patients :

* Age over 18 years old
* Signed informed consent
* 5 year old psoriasis at least
* At least one skin lesion over 2 cm
* Without any articular symptoms
* Without any DMARDs
* Without anticoagulant treatments or coagulation disease
* With normal articular and enthesis sonography
* For psoriatic arthritis patients :

* Age over 18 years old
* Signed informed consent
* Psoriatic arthritis according to CASPAR criteria
* Without any DMARDs
* Without anticoagulant treatments or coagulation disease
* With at least one synovitis at inclusion
* For controls

* Age and sex matched with a patient without any rheumatic or dermatologic medical conditions
* No treatment with corticosteroïds or non-steroïdial anti-inflammatory drugsAge over 18 years old

Exclusion Criteria

▪ For psoriasis patients :

* Joint damage according to CASPAR criteria
* Echography activity in favor of chronic inflammatory rheumatism
* For patients and controls:
* Without social protection rights
* People under judiciary protection, of less than 18 years old, pregnant woman, breast feeding women, jailed patients.

Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes